Setd2缺陷与Kras突变协同表观遗传重塑驱动幼年型粒单核细胞白血病发生及MEK抑制剂敏感性
研究探讨Setd2缺陷与Kras突变在幼年型粒单核细胞白血病(JMML)中的协同作用。Kras突变JMML携带较低H3K36三甲基化标记,Setd2缺失缩短KrasG12D/+小鼠疾病潜伏期并增强髓系祖细胞增殖。机制上Setd2缺失通过降低Dusp1基因体H3K36me3水平过度激活ERK1/2,MEK抑制剂与Setd2抑制剂联合在体外有效抑制白血病细胞系恶性生长。
要点
- Kras突变JMML中H3K36三甲基化标记水平较低
- Setd2缺失缩短KrasG12D/+小鼠JMML疾病潜伏期
- MEK与Setd2抑制剂联合在体外抑制白血病细胞系恶性生长
核心结论
- Setd2缺陷与Kras突变协同通过表观遗传重塑促进JMML发生,靶向ERK信号与Setd2可能为RAS介导白血病提供治疗思路。
研究设计与样本
- 研究采用KrasG12D/+介导的JMML小鼠模型及Setd2敲除小鼠,结合细胞功能实验与体外药物处理人及小鼠白血病细胞系。
主要发现
- Kras突变JMML携带较低H3K36三甲基化标记,Setd2缺失缩短KrasG12D/+小鼠疾病潜伏期。
- Setd2缺陷扰乱KrasG12D/+突变小鼠髓系祖细胞分化并增强其增殖能力。
- Setd2缺失与Kras突变共表达促进细胞周期进展、增强集落形成能力并逃避凋亡。
- Setd2-/-;KrasG12D/+共突变小鼠髓系祖细胞通过降低Dusp1基因体H3K36me3水平过度激活ERK1/2。
- MEK抑制剂与Setd2抑制剂联合在体外有效抑制人和小鼠白血病细胞系的恶性生长。
临床怎么用
- 原文结论认为靶向ERK信号与Setd2为致癌RAS介导的白血病提供了概念性治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukaemia (JMML) primarily stems from the Rat Sarcoma (RAS)/Extracellular Signal-Regulated Kinase (ERK) pathway mutations, and currently, there are no effective regimens against JMML, yet various studies have highlighted the importance of deciphering secondary genetic and/or epigenetic alterations in pursuit of treatments. Setd2-mediated-H3K36me3 participates in myriad biological functions and primarily serves as a tumour suppressor gene in carcinogenesis. However, little is known about the synergism between Setd2 deficiency and Kras mutation during JMML onset and progression. Herein, we reveal that Kras-mutant JMML possesses a lower H3K36 trimethylation mark, and Setd2 ablation in the KrasG12D/+-mediated JMML model shortens the disease latency. Phenotypically, Setd2 deficiency perturbs myeloid progenitor cell differentiation in KrasG12D/+ mutant mice and confers enhanced proliferative ability. Furthermore, the functional studies demonstrate that concurrent Setd2 depletion and Kras mutation expression promote cell cycle progression and enhance colony-forming ability while escaping apoptosis. Mechanistically, myeloid progenitor cells derived from Setd2-/-; KrasG12D/+ co-mutant mice hyperactivate ERK1/2 by reducing the H3K36me3 level on the Dusp1 gene body. Interestingly, a combination of mitogen-activated protein kinase (MEK) and Setd2 inhibitors effectively inhibits the malignant growth of human and mouse leukaemia cell lines in vitro. Hence, the current project provides strong concepts for targeting ERK signalling and Setd2 in oncogenic RAS-mediated leukaemia.
引用
- Munyurangabo G, Zhang L, Zhou Y, et al. Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity. Br J Haematol. 2025. PMID: 40755378. doi:10.1111/bjh.70060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。